StockWatch
·

Shalby Ltd

BSE: 540797

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
250.61
-3.3%+9.1%
Expenditure
219.05
-2.7%+10.0%
Net Profit
23.50
-6.2%+19.0%
OPM %
16.47%
-0.27pp-0.93pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0072.54145.08217.62290.15Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

9% growth masks hospital margin squeeze; Gurgaon breakout doesn't offset core pressure

hospital margin · Gurgaon growth · PAT collapse

Result verdictFollow-upQ2 FY2707 Nov 20266 minPharma & Healthcare

9% growth masked by margin compression; Gurgaon bright spot offsets hospital headwinds

hospital expansion · Gurgaon scaling · margin pressure

TranscriptDeep diveQ2 FY2707 Nov 20266 minPharma & Healthcare

Shalby consolidated PAT up 8% YoY to ₹7.9 Cr as Medtech losses widen further

hospital services · medtech losses · margin compression

ResultsQ2 FY2703 Nov 20263 minPharma & Healthcare
Latest
Board Meeting3 Nov, 6:24 pm

Shalby consolidated PAT up 8% YoY to ₹7.9 Cr as Medtech losses widen further

Shalby's consolidated revenue came in at ₹313.17 Cr (+9.7% YoY, -5.5% QoQ) and consolidated PAT at ₹7.89 Cr (+8.4% YoY, -24.9% QoQ) for Q2 FY27. No quarter-specific street estimate for Q2 FY27 could be located (trackers show only full-year FY27 consensus — EPS ₹4.20, +30% — with a near-unanimous Buy rating), so vs-street is unknown rather than graded. NPM was essentially flat YoY at 2.52% (vs 2.51%) but down sequentially from 3.10% in Q1 FY27; OPM came in at 13.22%, down from 14.58% a year ago though up from Q1's 12.56%. The Healthcare Services segment, the core of the business, grew PBT 9.8% YoY to ₹28.11 Cr on 12.1% revenue growth to ₹283.21 Cr — consistent with management's push toward the 20% hospital EBITDA margin target it set out for FY27 in the August 2026 concall, though no EBITDA breakout is disclosed to confirm the exact trajectory. Working against this, the Manufacturing & Trading of Implants (Medtech) segment's loss widened 78% YoY to ₹11.64 Cr on an 8.8% revenue decline to ₹29.97 Cr — the opposite of management's guidance that regulatory changes would bring Medtech to double-digit EBITDA margins within 6-9 months. The segment's deterioration coincides with Shalby Medtech CEO Deepak Anand's resignation on August 18, 2026, with no replacement named in this filing. No management press release accompanies this result, so there is no company framing to reconcile against the numbers. Standalone PAT of ₹23.50 Cr (EPS ₹2.19) is well above consolidated PAT of ₹7.89 Cr (EPS ₹0.73); the gap is entirely subsidiary-level losses, chiefly Medtech, consolidating down group profit. Both statements carry no exceptional items this quarter or a year ago, so YoY growth is on a clean base. Separately, the board approved appointing Shanay Vikram Shah and Tushar Shah as Whole-Time/Executive directors, subject to a shareholder postal ballot due December 5, 2026 — a governance move unconnected to this quarter's operating print. The Jabalpur hospital's registration was suspended after a fire on October 14, 2026 and operations fully resumed October 28, 2026 — both dates fall after this September 30 quarter-end, so the roughly two-week disruption sits in Q3 FY27, not this result, and is a watch item for the next print rather than a driver of this one.

3 Nov 2026, 06:24 pm

Corporate Events

Board MeetingSHALBY
2026
3Nov

Board Meeting

Consider and approve the unaudited financial results (Standa…

BSE Filing ↗
Board MeetingSHALBY
2026
10Sep

Board Meeting

The 22nd Annual General Meeting of the shareholders of the C…

BSE Filing ↗
Board MeetingSHALBY
2026
12Aug

Board Meeting

The Board of Directors considered and approved the appointme…

BSE Filing ↗
Board MeetingSHALBY
2026
5Aug

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingSHALBY
2026
30Jul

Board Meeting

The Management Committee of Directors approved availing of w…

BSE Filing ↗
Board MeetingSHALBY
2025
3Feb

Board Meeting

Consider and approve the Un-audited Standalone and Consolida…

BSE Filing ↗
Board MeetingSHALBY
2024
30Oct

Board Meeting

Approval Of Unaudited Standalone And Consolidated Financial …

BSE Filing ↗
Board MeetingSHALBY
2024
7Feb

Board Meeting

Consider and approve the Unaudited Financial Results (Standa…

BSE Filing ↗
Board MeetingSHALBY
2023
27Oct

Board Meeting

Consider and approve Unaudited Standalone And Consolidated F…

BSE Filing ↗